Challenger Treats Zika Virus

Challenger Treats Zika Virus Purpose of review Arthropod-borne viruses (arboviruses) are zoonotic, and the common vectors are ticks and hematophagous mosquitoes. Currently, dengue, chikungunya, yellow fever, West Nile, and Japanese encephalitis virus infections have been causing worldwide concerns. In 2015, a large outbreak was documented with another mosquito-borne flavivirus, the Zika virus (ZIKV), and ravaging South and Central Americas and the Caribbean. ZIKV was declaring a public health emergency, because of the clinical evidence neurological complications. Recent findings The flavivirus infection is difficult to differentiate only with clinical manifestation. It has been reported 2366 cases of microcephaly or congenital defects associated with ZIKV in Brazil, and the mechanism or processes that lead to these neurological complications are still under investigation. No antivirals are available to treat ZIKV infection, leading to no option to prevent the fetal infection during pregnancy which could avoid the congenital Zika syndrome. In this review, we will describe the drugs that are being tested in vitro and in animal models against ZIKV. Summary We reviewed several publications that test the compounds for the treatment of ZIKV disease. We conclude that some of these compounds testing in vitro and in vivo have shown a therapeutic possibilities to consider and to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Treatment Options in Infectious Diseases Springer Journals
Loading next page...
 
/lp/springer_journal/challenger-treats-zika-virus-XzRrkXaSPF
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Infectious Diseases
eISSN
1534-6250
D.O.I.
10.1007/s40506-018-0160-1
Publisher site
See Article on Publisher Site

Abstract

Purpose of review Arthropod-borne viruses (arboviruses) are zoonotic, and the common vectors are ticks and hematophagous mosquitoes. Currently, dengue, chikungunya, yellow fever, West Nile, and Japanese encephalitis virus infections have been causing worldwide concerns. In 2015, a large outbreak was documented with another mosquito-borne flavivirus, the Zika virus (ZIKV), and ravaging South and Central Americas and the Caribbean. ZIKV was declaring a public health emergency, because of the clinical evidence neurological complications. Recent findings The flavivirus infection is difficult to differentiate only with clinical manifestation. It has been reported 2366 cases of microcephaly or congenital defects associated with ZIKV in Brazil, and the mechanism or processes that lead to these neurological complications are still under investigation. No antivirals are available to treat ZIKV infection, leading to no option to prevent the fetal infection during pregnancy which could avoid the congenital Zika syndrome. In this review, we will describe the drugs that are being tested in vitro and in animal models against ZIKV. Summary We reviewed several publications that test the compounds for the treatment of ZIKV disease. We conclude that some of these compounds testing in vitro and in vivo have shown a therapeutic possibilities to consider and to

Journal

Current Treatment Options in Infectious DiseasesSpringer Journals

Published: May 4, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off